Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
51
CTMX Quote, Financials, Valuation and Earnings
Last price:
$3.96
Seasonality move
:
11.81%
Day range:
$3.92 - $4.09
52-week range:
$0.40 - $4.62
Dividend yield:
0%
P/E ratio:
9.45x
P/S ratio:
4.01x
P/B ratio:
6.23x
Volume:
929.8K
Avg. volume:
3.2M
1-year change:
240.52%
Market cap:
$669.3M
Revenue:
$138.1M
EPS (TTM):
$0.42
Analysts' Opinion
-
Consensus RatingCytomX Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.07, CytomX Therapeutics, Inc. has an estimated upside of 79.02% from its current price of $3.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -51.9% downside risk from its current price of $3.95.
Fair Value
-
According to the consensus of 6 analysts, CytomX Therapeutics, Inc. has 79.02% upside to fair value with a price target of $7.07 per share.
CTMX vs. S&P 500
-
Over the past 5 trading days, CytomX Therapeutics, Inc. has underperformed the S&P 500 by -8% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
CytomX Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CytomX Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter CytomX Therapeutics, Inc. reported revenues of $6M.
Earnings Growth
-
CytomX Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter CytomX Therapeutics, Inc. reported earnings per share of -$0.09.
Enterprise value:
531.2M
EV / Invested capital:
4.70x
Price / LTM sales:
4.01x
EV / EBIT:
22.95x
EV / Revenue:
4.68x
PEG ratio (5yr expected):
0.06x
EV / Free cash flow:
-7.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
21.75x
Gross Profit (TTM):
$112.4M
Return On Assets:
20.2%
Net Income Margin (TTM):
24.66%
Return On Equity:
61.33%
Return On Invested Capital:
52.07%
Operating Margin:
-266.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $94.7M | $126.6M | $113.6M | $33.4M | $6M | |
| Gross Profit | $88.8M | $124.8M | $112.4M | $33M | $5.8M | |
| Operating Income | -$6.9M | $6.7M | $23.1M | $4.1M | -$15.9M | |
| EBITDA | -$920K | $8.6M | $24.4M | $4.5M | -$15.7M | |
| Diluted EPS | -$0.16 | $0.17 | $0.42 | $0.07 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $241M | $200.3M | $201.2M | $124.2M | $149.2M | |
| Total Assets | $371.2M | $226.5M | $221.2M | $139M | $158.3M | |
| Current Liabilities | $99.8M | $97.8M | $146.8M | $119.2M | $41M | |
| Total Liabilities | $259.6M | $198M | $272.4M | $162.4M | $50.9M | |
| Total Equity | $111.7M | $28.5M | -$51.2M | -$23.5M | $107.4M | |
| Total Debt | $22.5M | $15.1M | $10.6M | $5.6M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.5M | -$88.3M | -$72.3M | -$20.7M | -$15.5M | |
| Cash From Investing | -$63.7M | $97.4M | -$30.2M | $18.2M | $439K | |
| Cash From Financing | $30.2M | $5.5M | $96.1M | -- | $253K | |
| Free Cash Flow | -$36.2M | -$88.8M | -$72.4M | -$20.7M | -$15.4M | |
CTMX
Sector
Market Cap
$669.3M
$28.5M
Price % of 52-Week High
85.5%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-18.01%
-1.33%
1-Year Price Total Return
240.52%
-20.32%
Beta (5-Year)
2.371
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.10
200-day SMA
Buy
Level
$2.17
Bollinger Bands (100)
Buy
Level
2.1 - 3.7
Chaikin Money Flow
Buy
Level
28.3M
20-day SMA
Sell
Level
$3.96
Relative Strength Index (RSI14)
Buy
Level
52.29
ADX Line
Buy
Level
18.53
Williams %R
Neutral
Level
-41.4365
50-day SMA
Buy
Level
$3.65
MACD (12, 26)
Buy
Level
0.13
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
41.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.4833)
Sell
CA Score
(Annual)
Level (-2.4134)
Sell
Beneish M-Score
(Annual)
Level (2.1777)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.869)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, CTMX has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CTMX average analyst price target in the past 3 months is $7.07.
-
Where Will CytomX Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that CytomX Therapeutics, Inc. share price will rise to $7.07 per share over the next 12 months.
-
What Do Analysts Say About CytomX Therapeutics, Inc.?
Analysts are divided on their view about CytomX Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CytomX Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is CytomX Therapeutics, Inc.'s Price Target?
The price target for CytomX Therapeutics, Inc. over the next 1-year time period is forecast to be $7.07 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CTMX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CytomX Therapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CTMX?
You can purchase shares of CytomX Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CytomX Therapeutics, Inc. shares.
-
What Is The CytomX Therapeutics, Inc. Share Price Today?
CytomX Therapeutics, Inc. was last trading at $3.96 per share. This represents the most recent stock quote for CytomX Therapeutics, Inc.. Yesterday, CytomX Therapeutics, Inc. closed at $3.95 per share.
-
How To Buy CytomX Therapeutics, Inc. Stock Online?
In order to purchase CytomX Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CTMX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CTMX
Sector
P/E ratio
9.45x
23.75x
PEG ratio
0.06x
-0.01x
P/B ratio
6.23x
1.83x
Price / LTM sales
4.01x
1.60x
Growth Metrics
CTMX
Sector
Revenue growth
-82.16%
4.85%
Earnings growth
-228.08%
11.11%
Revenue (5-year growth)
19.16%
6.45%
Earnings forecast
-$0.04
-$0.20
Profitability
CTMX
Sector
Profitability FY 2024
$136.3M
$3.6M
Return on invested capital
52.07%
-30.98%
Return on assets
20.2%
-27.62%
Return on equity
61.33%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
CTMX
Sector
Total cash
$143.6M
$27.2M
Short term investments
$62.6M
$25.7M
Total assets
$122.6M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
